sorafenib + cisplatin + fluorouracil

This is a **combination chemotherapy regimen** consisting of three drugs: **sorafenib**, **cisplatin**, and **fluorouracil** (5-FU). - **Sorafenib** is a multikinase inhibitor that targets tumor cell proliferation and angiogenesis, primarily by inhibiting receptors such as RAF kinases, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR). - **Cisplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, inhibiting DNA synthesis and function and inducing apoptosis. - **Fluorouracil (5-FU)** is a pyrimidine analog that inhibits thymidylate synthase, thereby blocking DNA replication and RNA function. The combination has been investigated in patients with **recurrent or metastatic nasopharyngeal carcinoma (NPC)** and **advanced hepatocellular carcinoma (HCC)**. In clinical trials, this regimen demonstrated feasibility and tolerability, with notable efficacy for these indications, including substantial objective response rates and manageable toxicity profiles[1][2][3]. Developers and study sponsors include academic cancer centers and clinical research groups in Asia. The therapy is generally administered as follows: sorafenib orally, cisplatin and 5-FU via intravenous or hepatic arterial infusion, typically in 21- or 28-day cycles[1][2][3].

Brand names

Nexavar

Other names

sorafenib + cisplatin + 5-fluorouracil